Collegium Pharmaceutical Inc - Company Profile
Powered by 
All the data and insights you need on Collegium Pharmaceutical Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Collegium Pharmaceutical Inc Strategy Report
- Understand Collegium Pharmaceutical Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Collegium Pharmaceutical Inc (Collegium) is a specialty pharmaceutical company that focuses on the development and commercialization of innovative drugs for treating patients suffering from pain. It develops products based on its DETERx platform technology. DETERx offers extended-release drug delivery, while protecting against common methods of abuse and tampering. The company's lead product, Xtampza ER is designed to provide adequate pain control. Its other products include Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy; and Nucynta IR for the management of acute pain severe enough to require an opioid analgesic. The company is headquartered in Stoughton, Massachusetts, the US.
Headquarters
United States of America
Address
100 Technology Center Dr, Stoughton, Massachusetts, 02072-4710
Website
www.collegiumpharma.com
Telephone
1 781 7133699
No of Employees
197
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
COLL (NASD)
Revenue (2022)
$566.8M
22.2%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
292.6%
(2022 vs 2021)
Market Cap*
$1.2B
Net Profit Margin (2022)
XYZ
257.7%
(2022 vs 2021)
* As of and is in US$
Collegium Pharmaceutical Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Products | Xtampza ER |
| Oral Formulation of Oxycodone | DETERx |
| Immediate Release Formulation of Tapentadol | Nucynta |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | Collegium Pharmaceutical Inc | Teva Pharmaceutical Industries Ltd | Mallinckrodt Plc | Societal CDMO Inc | Elite Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Israel | Ireland | United States of America | United States of America |
| City | Stoughton | Tel Aviv | Dublin | Exton | Northvale |
| State/Province | Massachusetts | Tel Aviv | - | Pennsylvania | New Jersey |
| No. of Employees | 197 | 35,001 | 2,800 | 258 | 53 |
| Entity Type | Public | Public | Private | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Michael T. Heffernan | Chairman | Executive Board | 2018 | 57 |
| Joseph Ciaffoni | Chief Executive Officer; Director; President | Executive Board | 2018 | 51 |
| Colleen Tupper | Executive Vice President; Chief Financial Officer | Senior Management | 2021 | 47 |
| Shirley Kuhlmann | Chief Administrative Officer; Executive Vice President; General Counsel | Senior Management | 2018 | 40 |
| Kelly Clements | Vice President; Chief People Officer | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer